ProShares Ultra Nasdaq Biotechnology Rating → Missed NVDA? Buy this AI stock NOW (From Chaikin Analytics) (Ad) Free BIB Stock Alerts $54.47 -0.95 (-1.71%) (As of 05/10/2024 ET) Add Compare Share Share RatingsStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestSocial MediaStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestSocial Media ProShares Ultra Nasdaq Biotechnology Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BIB Aggregate RatingModerate Buy2.56Holdings in BIB have an aggregate rating of Moderate Buy based on 555 analyst ratings issued in the past year covering 43 companies (54.2% of the portfolio).BIB Aggregate Price Target$64.5918.58% UpsideHigh Prediction$85.01Average Prediction$64.59Low Prediction$46.49Holdings in BIB have an aggregate price target of $64.59 and a range of $46.49 to $85.01 covering 43 companies (54.2% of the portfolio).BIB Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy6 Buy rating(s)Moderate Buy26 Moderate Buy rating(s)Hold10 Hold rating(s)Reduce0 Reduce rating(s)Sell1 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by ProShares Ultra Nasdaq Biotechnology Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 43 BIB Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.47%AMGNAmgen$310.15-0.9%5 of 5 stars2.52$305.65 -1.5%21Analyst Forecast5.64%REGNRegeneron Pharmaceuticals$973.80+0.6%4 of 5 stars2.70$981.71 0.8%20Positive News5.42%VRTXVertex Pharmaceuticals$422.78+0.9%4 of 5 stars2.48$432.18 2.2%25Earnings ReportAnalyst Forecast5.11%GILDGilead Sciences$65.96+2.1%5 of 5 stars2.39$83.69 26.9%18Analyst Revision3.47%MRNAModerna$117.31-4.4%3 of 5 stars2.25$126.89 8.2%16Analyst ForecastInsider Selling3.23%AZNAstraZeneca$77.18-0.6%2 of 5 stars2.57$81.00 4.9%72.30%BIIBBiogen$221.50-0.6%5 of 5 stars2.65$288.46 30.2%26Positive News1.39%ALNYAlnylam Pharmaceuticals$150.47-0.6%4 of 5 stars2.59$216.19 43.7%17Analyst ForecastShort Interest ↑Analyst Revision1.36%ILMNIllumina$110.53-0.7%5 of 5 stars2.30$164.65 49.0%20Analyst ForecastShort Interest ↓1.13%BMRNBioMarin Pharmaceutical$81.03-0.8%5 of 5 stars2.63$107.50 32.7%19Short Interest ↑1.02%VTRSViatris$11.16-0.5%1 of 5 stars1.33$11.00 -1.4%3Earnings ReportDividend AnnouncementNews Coverage1.02%NBIXNeurocrine Biosciences$136.70-2.1%5 of 5 stars2.74$147.88 8.2%230.97%SNYSanofi$49.28+1.2%3 of 5 stars2.40$55.00 11.6%5Short Interest ↑News Coverage0.92%RPRXRoyalty Pharma$28.09+0.4%5 of 5 stars3.00$46.75 66.4%4Earnings ReportAnalyst DowngradeNews Coverage0.91%SRPTSarepta Therapeutics$131.82-0.4%4 of 5 stars2.79$160.60 21.8%140.90%UTHRUnited Therapeutics$264.27-0.7%5 of 5 stars2.90$308.78 16.8%10Insider Selling0.88%ARGXargenx$374.63-2.1%3 of 5 stars2.71$527.84 40.9%21Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews Coverage0.88%INCYIncyte$53.06-0.8%5 of 5 stars2.47$74.93 41.2%17Short Interest ↑0.88%MEDPMedpace$390.19-2.3%5 of 5 stars2.80$443.00 13.5%5Insider SellingNews Coverage0.67%ROIVRoivant Sciences$11.13-1.1%3 of 5 stars2.90$16.90 51.8%10Positive News0.65%BNTXBioNTech$91.67-0.4%2 of 5 stars2.27$118.82 29.6%11Analyst ForecastShort Interest ↑Analyst Revision0.57%ASNDAscendis Pharma A/S$133.46+0.2%1 of 5 stars2.88$173.88 30.3%80.52%PCVXVaxcyte$65.19-0.6%1 of 5 stars3.00$78.50 20.4%4Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage0.50%JAZZJazz Pharmaceuticals$109.63-3.1%5 of 5 stars2.85$192.75 75.8%13Insider Selling0.49%BGNEBeiGene$161.13-4.5%3 of 5 stars2.80$251.93 56.4%10Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage0.49%CYTKCytokinetics$62.10-3.0%4 of 5 stars2.87$81.60 31.4%15Earnings ReportAnalyst ForecastInsider SellingAnalyst RevisionNews Coverage0.48%RVMDRevolution Medicines$37.25-0.5%4 of 5 stars3.10$41.60 11.7%10Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage0.48%EXELExelixis$21.37-1.8%5 of 5 stars2.63$26.33 23.2%16Short Interest ↑0.48%ITCIIntra-Cellular Therapies$64.96-0.9%5 of 5 stars2.90$90.17 38.8%10Earnings ReportAnalyst ForecastAnalyst Revision0.48%BPMCBlueprint Medicines$106.70-1.5%1 of 5 stars2.50$100.31 -6.0%16Short Interest ↑Analyst Revision0.44%IONSIonis Pharmaceuticals$39.08-1.0%4 of 5 stars2.71$59.54 52.4%14Earnings ReportAnalyst ForecastInsider SellingShort Interest ↓0.44%IBRXImmunityBio$8.12+0.7%0 of 5 stars2.00$6.00 -26.1%1Gap Up0.42%APLSApellis Pharmaceuticals$41.99-1.2%4 of 5 stars2.87$76.67 82.6%15Earnings ReportAnalyst ForecastInsider SellingShort Interest ↑Analyst RevisionNews Coverage0.37%HALOHalozyme Therapeutics$43.15-1.6%5 of 5 stars2.83$53.14 23.2%6Analyst Forecast0.36%BBIOBridgeBio Pharma$29.10+1.3%5 of 5 stars2.80$47.82 64.3%10Short Interest ↑0.33%MDGLMadrigal Pharmaceuticals$205.25-0.8%5 of 5 stars2.73$345.09 68.1%11Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage0.33%KRYSKrystal Biotech$154.76-2.5%5 of 5 stars3.00$171.00 10.5%9Earnings ReportShort Interest ↑Analyst RevisionNews Coverage0.33%CRSPCRISPR Therapeutics$51.17-4.4%3 of 5 stars2.35$73.93 44.5%17Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionNews Coverage0.31%ALPNAlpine Immune Sciences$64.94+0.2%2 of 5 stars2.27$50.33 -22.5%11Short Interest ↓Positive News0.30%NUVLNuvalent$65.48-3.0%3 of 5 stars2.90$90.78 38.6%10Earnings ReportInsider SellingAnalyst RevisionNews Coverage0.30%IMVTImmunovant$29.39-1.0%3 of 5 stars3.00$48.00 63.3%17Short Interest ↑0.29%ALKSAlkermes$24.05-0.9%5 of 5 stars2.50$35.38 47.1%10Positive News0.28%IOVAIovance Biotherapeutics$10.97-18.4%5 of 5 stars3.00$24.64 124.7%10Earnings ReportAnalyst ForecastNews CoverageGap DownHigh Trading Volume This page (NASDAQ:BIB) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
